Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
13.08
+0.23 (1.79%)
At close: Dec 20, 2024, 4:00 PM
12.52
-0.56 (-4.29%)
After-hours: Dec 20, 2024, 6:38 PM EST
Syndax Pharmaceuticals Employees
Syndax Pharmaceuticals had 184 employees as of December 31, 2023. The number of employees increased by 77 or 71.96% compared to the previous year.
Employees
184
Change (1Y)
77
Growth (1Y)
71.96%
Revenue / Employee
$86,957
Profits / Employee
-$1,614,467
Market Cap
1.12B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Tilray Brands | 2,650 |
Establishment Labs Holdings | 908 |
Weave Communications | 844 |
CareDx | 643 |
BioLife Solutions | 414 |
Ardelyx | 267 |
Innoviva | 112 |
Pulse Biosciences | 56 |
SNDX News
- 12 days ago - Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial - PRNewsWire
- 13 days ago - Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting - PRNewsWire
- 17 days ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 24 days ago - Syndax Announces Participation at the Citi 2024 Global Healthcare Conference - PRNewsWire
- 5 weeks ago - US FDA approves Syndax's blood cancer drug - Reuters
- 5 weeks ago - Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation - PRNewsWire
- 5 weeks ago - Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity - Seeking Alpha
- 5 weeks ago - Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib - PRNewsWire